Every 8-K that NeOnc Technologies Holdings, Inc. (NTHI) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow NTHI and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full NTHI filings page.
NeOnc Technologies Holdings, Inc. (NTHI) said it is scheduled to meet in person with the FDA on November 17, 2026, for an End-of-Phase 1 Type B meeting about NEO212. NeOnc plans to seek feedback on the clinical program, including the proposed patient population, trial design, endpoints, dose selection, evidence for a future marketing application, and whether a proposed trial design could support a potential accelerated approval pathway. The meeting's scheduling does not establish FDA agreement on a trial design or regulatory pathway.
NeOnc says it completed Phase 1 dose escalation. Dose escalation was discontinued following a dose-limiting toxicity at 810 mg once daily on Days 1 through 5 of a 28-day cycle; 610 mg was selected as the recommended Phase 2 dose. The company reports FDA authorization in September 2025 to proceed with the Phase 2a and Phase 2b portions of the study. It also describes individual Phase 1 outcomes: about 60% tumor reduction and disease control lasting 21 treatment months in one patient with recurrent glioblastoma, and stable disease lasting about 16 months in a patient with lung cancer metastatic to the brain. The company cautions that these outcomes do not establish efficacy and require confirmation in larger studies.
NEONC TECHNOLOGIES HOLDINGS, INC. (symbol: NTHI) is the issuer of record for a Form 8-K filing submitted to the SEC.
NeOnc Technologies Holdings, Inc. (NTHI) reported that Executive Chairman, President and CEO Amir F. Heshmatpour bought an additional 35,000 shares of common stock in the open market on September 15, 2026, for approximately $115,400 at a weighted average price of about $3.30 per share.
Since the company announced positive topline Phase 2a results for intranasal NEO100 on August 12, 2026, Mr. Heshmatpour has accumulated 111,000 shares for roughly $418,700, while Founder and Chief Medical Officer Thomas C. Chen has purchased 49,016 shares for about $210,000, for combined open‑market purchases of 160,016 shares totaling approximately $629,000.
The Phase 2a NEO100-01 study met its primary endpoint, with six‑month progression‑free survival of 48.9% versus a 20% benchmark (p = 0.0047) and median overall survival of 26.09 months, and follows a previously announced $15 million registered direct offering, while NeOnc’s second program, NEO212, has completed Phase 1 dose escalation and set a recommended Phase 2 dose.
NeOnc Technologies Holdings, Inc. (NTHI) entered into securities purchase agreements for a registered direct offering of 3,571,430 shares of common stock (or pre-funded warrants in lieu) and accompanying warrants to purchase up to 3,571,430 shares at a combined purchase price of $4.20 per share (or $4.1999 per pre-funded warrant) and warrant. Gross proceeds are estimated at $15 million before a 7.0% placement fee and expenses. Warrants are immediately exercisable at $4.20 per share and expire five years from issuance; pre-funded warrants have a $0.0001 exercise price and remain exercisable until fully exercised, both subject to beneficial ownership limitations.
The transaction is a takedown from NeOnc’s effective Form S-3 shelf registration. The company plans to use net proceeds for working capital and general corporate purposes and to redeem Series A Convertible Preferred Stock. Closing is expected on or about September 10, 2026, subject to customary conditions. NeOnc agreed to a 30-day restriction on new equity issuances, while the Chief Executive Officer and Chief Medical Officer entered into 90-day lock-up agreements.
NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI) reports a change in board governance. This amendment updates a prior report that announced the appointment of Nasim Shomali to the Board of Directors effective July 1, 2026. The only new disclosure is her board committee assignment.
On August 18, 2026, the Board appointed Nasim Shomali to serve as a member of the Audit Committee, effective immediately. Following this appointment, the Audit Committee consists of three directors: Bader Almonawer (Chair), Jim Delshad, and Nasim Shomali. All other aspects of the earlier report remain unchanged.
NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI) reported the results of its 2026 annual stockholders meeting held on August 14, 2026. Stockholders of record on June 15, 2026, holding 25,931,865 shares of common stock, were entitled to vote, and 20,208,635 shares (or 77.92%) were present, constituting a quorum.
Stockholders elected Class I directors Victoria Medvec, Ph.D. and Steven L. Giannotta, M.D. to terms ending at the 2029 annual meeting. They received approximately 16.96 million and 16.95 million "For" votes, respectively, with broker non-votes reported. Stockholders also approved an amendment to the Company’s 2023 Equity Incentive Plan, ratified the appointment of CBIZ CPAs P.C. as independent registered public accounting firm for the year ending December 31, 2026, and approved the potential adjournment of the meeting if necessary to obtain a quorum or additional approvals.
NeOnc Technologies Holdings, Inc. reported top-line results from the Phase 2a portion of its NEO100-01 trial in recurrent IDH1-mutant high-grade glioma. The single-arm study enrolled 24 patients, mostly recurrent Grade IV tumors, using intranasal delivery of NEO100 to bypass the blood–brain barrier.
The trial met its primary endpoint: progression-free survival at six months (PFS6) was 48.9%, compared with a pre-specified 20% historical benchmark, with a reported p-value of 0.0047. Median overall survival from recurrence was 26.09 months, versus a cited salvage-therapy benchmark of roughly six to nine months. Six-month overall survival was 86.7%, and 12‑month overall survival was 60.9%.
The company reported disease control (partial response plus stable disease) in 66.7% of patients and described long-term survival across combined Phase 1/2 experience, where 55% of 29 patients lived more than one year post‑recurrence. NeOnc plans to discuss a randomized Phase 3 trial with the FDA, targeting lomustine as the comparator and seeking an accelerated approval design.
NeOnc Technologies Holdings reported positive topline Phase 2a results from NEO100-01, an open-label study of intranasal NEO100 in recurrent or progressive Grade III/IV IDH1-mutant glioma after radiation and temozolomide. The study’s primary endpoint was met: six-month progression-free survival (PFS-6) was 48.9% by RANO 2.0 using Kaplan-Meier estimation (95% CI: 26.3–68.1), versus a 20% benchmark for standard care (p = 0.0047). Secondary outcomes were supportive, with median overall survival of 26.09 months from first NEO100 dose at recurrence, OS of 86.7% at six months, 60.9% at 12 months, and 54.1% at 24 months, and disease control in 66.7% of patients (8.3% partial response, 58.3% stable disease). Five of 24 patients remain on therapy, including one progression-free for about 19 months. NEO100 was administered intranasally at home four times daily and was described as generally well tolerated, with no major or dose-limiting toxicities reported. The company plans to request a Type B FDA meeting to align on a registrational development path and is outlining a proposed randomized Phase 3 trial intended to support Accelerated Approval, while emphasizing the limitations of the single-arm, 24-patient design and reliance on historical comparators.
NeOnc Technologies Holdings, Inc. reported second quarter 2026 results and highlighted progress in its CNS cancer pipeline. For the quarter ended June 30, 2026, GAAP total operating expenses were $14,069,887, including $5,651,913 of non-cash stock-based compensation, resulting in non-GAAP operating expenses of $8,417,974.
The company completed topline analysis of its fully enrolled Phase 2a NEO100 study in recurrent IDH1-mutant high-grade glioma and plans to present topline results on August 12, 2026. NeOnc also obtained UAE IND approvals for both NEO100 and NEO212, expanded clinical activities, reduced general and administrative expenses year over year, and added Nasim Shomali to its board. An investor conference call and webcast to review the NEO100 Phase 2a topline data is scheduled for August 12, 2026, at 5:30 a.m. Pacific / 8:30 a.m. Eastern.
NeOnc Technologies Holdings, Inc. announced that it received detailed written feedback from the U.S. Food and Drug Administration on the chemistry, manufacturing and controls development program for its NEO212 temozolomide‑perillyl alcohol conjugate. The feedback focuses on manufacturing, formulation, bioavailability work and the capsule‑to‑tablet transition for late‑stage development.
The written responses were provided in advance of a Type B End‑of‑Phase 1 meeting scheduled for July 9, 2026, which NeOnc canceled after determining that additional discussion was not required. NeOnc is integrating the FDA’s comments into its development plan, evaluating study design, manufacturing activities, timelines and costs, and expects to provide an updated plan. The feedback relates to CMC and does not constitute FDA approval of NEO212 or agreement on any future registrational trial design. NEO212 and NEO100 are in Phase II trials for central nervous system cancers, with patent protections extending to 2038 and programs advancing under FDA Fast Track and IND status.
NeOnc Technologies Holdings, Inc. reported a change on its Board of Directors. On June 27, 2026, Class II director Ming-Fu (Alan) Chiang, M.D., Ph.D., MBA, resigned from the Board and from the Scientific Advisory Board, and the company states his resignation was not due to any disagreement over operations, policies, or practices.
On July 1, 2026, the Board elected Nasim Shomali as a Class II director to serve until the 2027 annual meeting of stockholders. She previously served as a Strategy Executive at Accenture from April 2013 to April 2026, advising large companies on enterprise strategy and transformation. The company notes there is no arrangement under which she was selected, and discloses that Shomali is the niece of President, Chief Executive Officer and Executive Chairman Amir Heshmatpour.
NeOnc Technologies Holdings, Inc. reported that the Department of Health – Abu Dhabi has granted Investigational New Drug (IND) status for NEO100, its lead intranasal nose‑to‑brain cancer therapy. The authorization covers NEO100-01, NEO100-02, and NEO100-03 protocols from Phase 1 through Phase 2 in adults, plus a pediatric pathway for Phase 1 and Phase 1b.
NEO100 targets progressive or recurrent Grade III or IV gliomas and complements NeOnc’s existing UAE IND for its NEO212 program. In the United States, NEO100 holds FDA Orphan Drug, Fast Track, and Rare Pediatric Disease designations, and the NEO100-01 Phase 2a trial in recurrent IDH1-mutant high-grade glioma is fully enrolled, with top-line data expected by the end of July 2026.
NeOnc Technologies Holdings, Inc. reported that the Department of Health – Abu Dhabi has granted Investigational New Drug (IND) status in the United Arab Emirates for NEO212, its oral perillyl alcohol-temozolomide conjugate for aggressive brain tumors. This is the first international regulatory clearance for NEO212 following completion of Phase 1 evaluation.
The Phase 1 dose-escalation study established 610 mg as the recommended Phase 2 dose and showed early signs of clinical activity in heavily pretreated patients with recurrent glioblastoma and brain metastases. The new authorization is expected to support advancement into Phase 2 in the UAE, alongside ongoing U.S. FDA discussions on a potential registrational pathway.
Before enrolling patients in the UAE, NeOnc must obtain DOH Institutional Review Board approval and update its study documents and labeling. The clearance covers clinical research only and is not a marketing authorization. NeOnc has also applied in Abu Dhabi for several NEO100 programs, aiming to expand its brain cancer and neurological pipeline internationally.
NeOnc Technologies Holdings, Inc. entered into a Securities Purchase Agreement with accredited investors to sell up to $5,000,000 of Series A Convertible Preferred Stock in a private placement. Up to 6,000 preferred shares will be issued at $833.34 per share, each with a stated value of $1,000.
The preferred stock ranks senior to common stock in a liquidation and carries no general voting rights. The company may redeem all Series A shares at stated value within four months, with two one‑month extension options that each add $50 per share. If the company elects not to redeem, an additional $166.67 per share is added and the shares become convertible into common stock at 80% of the lowest closing price over the prior five trading days, subject to a $1.00 floor, a 19.99% conversion cap without stockholder approval, and a beneficial ownership limit of 4.99% or 9.99% per holder.
NeOnc Technologies Holdings used this report to share first quarter 2026 results and progress in its brain cancer programs. For the quarter ended March 31, 2026, GAAP net loss was $8.8 million, and non-GAAP normalized cash operating expenses were $6.1 million.
Clinically, the company completed Phase 1 dose escalation for NEO212 and set 610 mg as the recommended Phase 2 dose, while its Phase 2a NEO100 study moves toward an interim readout supported by previously reported 24% radiographic remission and 44% six‑month progression-free survival. NeOnc also arranged a $10 million PIPE financing led by Cinctive Capital and noted an open‑market insider share purchase of more than $500,000.
NeOnc Technologies Holdings, Inc. is raising capital through a series of private placements of common stock and five-year warrants. Across four Securities Purchase Agreements, the company has agreed to issue shares at $7.20 per share with accompanying warrants exercisable at $9.00 per share.
The latest, fourth agreement dated April 20, 2026 covers up to 406,694 shares and related warrants, with an initial closing of 277,777 shares and 277,777 warrants for approximately $2 million. Earlier agreements in January, February and March 2026 included multiple closings with institutional and other investors.
The company intends to use the net proceeds to fund NEO216 preclinical trials. The securities were issued under an exemption from registration provided by Section 4(a)(2) of the Securities Act, and NeOnc will file a resale registration statement for the shares and warrant shares within ten days of the initial closing under the fourth agreement.
NeOnc Technologies Holdings, Inc. reported that its Chairman and CEO, Amir Heshmatpour, recently bought approximately $300,000 of NTHI stock, signaling management’s confidence in the company. The update also explains the components of the company’s 2025 net loss and its current cash use.
For 2025, NeOnc recorded a net loss of about $62 million, with roughly 73% tied to non-cash stock-based compensation and one-time listing-related advisory fees. These non-cash and non-recurring items totaled $45.2 million, leaving normalized ongoing cash operating expenses of about $10.1 million. NeOnc also raised approximately $13.0 million in a Q1 2026 private placement, using part of the proceeds to repay short-term convertible debt and settle accrued obligations, and highlighted a reconciliation showing 2025 core operating cash burn of roughly $10.1 million.
NeOnc Technologies Holdings, Inc. established an at-the-market equity program allowing it to sell up to $75,000,000 of common stock through BTIG, LLC and A.G.P./Alliance Global Partners as placement agents. Sales may be made from time to time on the Nasdaq Global Market or other existing U.S. trading markets.
The company will pay the placement agents a cash commission equal to 3.0% of the gross sales price of shares sold and reimburse specified expenses. The shares will be issued under NeOnc’s previously filed Registration Statement on Form S-3 (File No. 333-294845), which was declared effective on April 9, 2026, and a related prospectus supplement filed April 10, 2026.
NeOnc Technologies Holdings, Inc. reported fourth quarter and full-year 2025 results and provided a business update focused on its central nervous system cancer pipeline. The company highlighted completion of NEO212’s Phase 1 dose escalation, establishing a recommended Phase 2 dose of 610 mg with early signs of possible anti-tumor activity in heavily pretreated patients.
NeOnc also reported that its NEO100 Phase 2a study in recurrent IDH1-mutant high-grade glioma is fully enrolled, with updated Phase 1/2a data showing a 24% radiographic remission rate, 44% six-month progression-free survival, and no significant toxicity. The company strengthened its balance sheet through a PIPE financing anchored by Cinctive Capital’s $10 million commitment, is planning a Type B End-of-Phase 1 FDA meeting for NEO212, and expects preliminary NEO100 Phase 2a data in approximately five months.
NeOnc Technologies Holdings, Inc. entered a third Securities Purchase Agreement on March 20, 2026 as part of a broader private financing program. This agreement covers up to 545,583 shares of common stock at $7.20 per share and five-year warrants to buy up to 545,583 shares at $9.00 per share. The initial closing on March 20, 2026 provided 138,889 shares and 138,889 warrants to one investor for $1,000,000. The company plans to use the net proceeds for working capital and relied on a private offering exemption under Section 4(a)(2) of the Securities Act, with a commitment to later file a resale registration statement for the shares and warrant shares.
NeOnc Technologies Holdings, Inc. appointed David Choi as Chief Accounting Officer, effective March 12, 2026. The company entered into an employment agreement providing a $162,500 annual base salary and a grant of 170,000 restricted shares under the 2023 Equity Incentive Plan.
Of these restricted shares, 53,333 vested on March 12, 2026, 58,333 will vest on the one-year employment anniversary, and 58,334 are performance-based, vesting upon achievement of specified metrics in his grant agreement. Choi, a CPA with over a decade of public-company accounting and controls experience, will lead accounting, financial reporting, internal controls, and governance as NeOnc advances its CNS cancer drug programs.
NeOnc Technologies Holdings, Inc. furnished an update on its oral brain cancer drug candidate NEO212, sharing full Phase 1 dose-escalation results and outlining next development steps. The Phase 1/2 trial reached Maximum Tolerated Dose at 810 mg in Cohort 5, and the Recommended Phase 2 Dose was set at 610 mg (Cohort 4), with 400 mg as the starting dose for the Phase 2a metastasis cohort.
Although Phase 1 was primarily a safety study, NeOnc reported early signs of anti-tumor activity, including durable disease control in heavily pretreated glioblastoma and brain metastasis patients. Across cohorts, the company highlighted low levels of systemic NEO212 metabolites and reported no clinically meaningful myelosuppression, hepatic, or renal toxicity, which are common concerns with standard temozolomide therapy.
NeOnc plans to move NEO212 into Phase 2 expansion cohorts focused on recurrent central nervous system cancers and intends to request a Type B (End-of-Phase 1) FDA meeting to discuss safety, pharmacology, preliminary efficacy, Phase 2 design, and a potential accelerated approval pathway.
NeOnc Technologies Holdings, Inc. disclosed that its wholly owned subsidiary NeOnc Technologies, Inc. has fully settled a contract dispute with Fox Infused, LLC. The dispute arose after NeOnc terminated a July 1, 2022 Intellectual Property License and Supply Agreement on April 25, 2023, which led to litigation and then arbitration. The parties had agreed to settle for a $600,000 payment tied to the company’s initial public offering or March 31, 2024. On February 27, 2026, NeOnc paid Fox Infused $737,920.77, including $137,920.77 in interest, and the matter is now fully resolved.
NeOnc Technologies Holdings, Inc. entered into a series of private financing deals to sell common stock and warrants to institutional and other investors. An earlier Securities Purchase Agreement allowed issuance of up to 2,222,222 shares at $7.20 per share and five-year warrants exercisable at $9.00 per share.
Under that agreement, the company first issued 1,388,888 shares and matching warrants to a single institutional investor for $10 million, then 86,361 shares and matching warrants to three investors for $621,804.11. A new Securities Purchase Agreement dated February 24, 2026 covers up to 746,973 additional shares and warrants on the same terms, with an initial closing of 201,390 shares and matching warrants to four investors for $1,450,004. NeOnc plans to use the net proceeds for working capital and will later file a resale registration statement for the shares and warrant shares.
NeOnc Technologies Holdings, Inc. is planning an investor conference call and webcast on March 4, 2026, at 6:00 a.m. Pacific / 9:00 a.m. Eastern Time. The company will present initial data from the Phase 1 dose-escalation portion of its NEO212-01 Phase 1/2 clinical trial.
Management and independent members of NeOnc’s Scientific Advisory Board will discuss safety and toxicity data, dose-escalation observations, pharmacokinetic findings, and planned regulatory next steps for NEO212, an oral bioconjugated temozolomide (TMZ) platform for central nervous system malignancies.
NeOnc Technologies Holdings, Inc. entered into a Securities Purchase Agreement to sell up to 2,222,222 shares of common stock at $7.20 per share and five-year warrants to buy up to 2,222,222 additional shares at an exercise price of $9.00 per share. An initial closing provided 1,388,888 shares and warrants for 1,388,888 shares to a single institutional investor for $10 million. The company plans additional closings and intends to use net proceeds to repay debt and for working capital. These securities are issued in a private placement under Section 4(a)(2), and the company will file a resale registration statement for the shares and warrant shares within ten days of the initial closing.
NeOnc Technologies Holdings, Inc. reported that it has released updated clinical results for its investigational therapy NEO100. The update covers an ongoing Phase 1/2a study and compassionate-use experience using intranasal NEO100 in patients with recurrent WHO Grade III/IV IDH1-mutant astrocytoma, a form of aggressive brain cancer. These details are provided in a press release dated December 15, 2025, which is included as an exhibit to the report.
The company furnished this information under a Regulation FD disclosure so that all investors receive the clinical update at the same time. The press release itself contains the specific clinical data and outcomes related to NEO100 in this patient group.
NeOnc Technologies Holdings (NTHI) furnished a Reg FD update announcing updated clinical results from ongoing Phase 1/2a and compassionate care studies of its investigational intranasal agent NEO100 in a 24-patient cohort with recurrent WHO Grade III/IV IDH1‑mutant astrocytoma.
The company also hosted an investor call to discuss the results and provided supporting materials. The press release, investor presentation, and call transcript are furnished as Exhibits 99.1, 99.2, and 99.3. The information under Item 7.01 is furnished, not filed, and is not subject to Section 18 liabilities or incorporation by reference except as specifically stated.
NeOnc Technologies Holdings, Inc. announced it will host an investor conference call and webcast on November 12, 2025 at 9:00 a.m. Eastern Time to present data updates from its ongoing Phase 1/2a NEO100-1 clinical trial and its compassionate use program.
The announcement was furnished under Item 7.01, and a related press release dated November 7, 2025 was attached as Exhibit 99.1.
NeOnc Technologies Holdings (NTHI) announced a leadership change. On October 31, 2025, Dr. Thomas Chen resigned as Chief Executive Officer and became Chief Medical Officer and Chief Scientific Officer, while remaining Vice Chairman. The Board appointed Amir Heshmatpour as Chief Executive Officer effective immediately; he also continues as President and Executive Chairman.
The Company agreed to pay Mr. Heshmatpour $1 per year until a formal employment agreement is finalized. He will be granted 1,200,000 shares of restricted stock under the 2023 plan, with one-half vesting on January 2, 2025 and the remainder vesting in twelve equal monthly installments thereafter.
The filing also summarizes prior related-party and financing items: AFH advisory fees of $500,000 in 2023 and an amended arrangement including an upfront payment of $2,500,000; a June 14, 2024 bridge loan conversion into 979,039 shares at $12 per share; an October 11, 2024 line of credit of up to $10.0 million at 10% interest with a warrant (cashlessly exercised for 164,500 shares in April 2025); and approximately $300,000 advanced in February 2025 with a 50% original issue discount, repaid after the direct listing.
NeOnc Technologies Holdings, Inc. (NTHI) announced a leadership change at its Middle East subsidiary. His Highness Sheikh Nahyan bin Zayed Al Nahyan will formally assume the role of Executive Chairman of NuroMENA Holdings Ltd., the company’s Middle East unit. The update was communicated via a press release.
The announcement was furnished under Item 7.01 and is not deemed “filed” under the Exchange Act. A copy of the press release is included as Exhibit 99.1.
NeOnc Technologies Holdings, Inc. reported that its previously announced $50 million strategic partnership is now expected to close no later than October 23, 2025, after receiving all required tax identification and regulatory approvals from the United Arab Emirates. This indicates the transaction has cleared key governmental and regulatory hurdles and is approaching completion.
The company shared this update through a press release furnished under a Regulation FD disclosure, meaning the information is being made broadly available to the market but is not treated as filed for liability purposes or automatically incorporated into other securities law documents unless specifically referenced.
NeOnc Technologies Holdings, Inc. has entered into a Master Services Agreement with Insights Pharmaceutical Research LLC (IROS), a UAE-based contract research organization affiliated with Group 42 Holding Ltd. and Mubadala Investment Company PJSC. Under this agreement, IROS will run clinical trials in the UAE for NeOnc, handling regulatory submissions, site selection and management, monitoring, data management and trial reporting in line with Good Clinical Practice and UAE/FDA rules.
The first work order covers a multi-site, randomized Phase 2b/3 study of intranasal NEO100 in patients with progressive or recurrent Grade III astrocytomas and glioblastoma multiforme, with an estimated budget of about $2.4 million in service fees and $0.1 million in pass-through costs, paid in four milestone-based installments. NeOnc keeps all rights to the clinical data, intellectual property and regulatory filings, and plans to transfer the MSA to its controlled UAE subsidiary, NuroCure, once that entity is incorporated.
NeOnc Technologies Holdings, Inc. filed a current report describing a regulatory milestone for its lead program. The company announced that the U.S. Food and Drug Administration has authorized it to proceed with Phase IIa/IIb of its NEO212-01 clinical trial, indicating clearance to advance this investigational therapy into the next stage of human testing. The update was communicated through a press release furnished as an exhibit to the report rather than filed for liability purposes under the securities laws.
NeOnc Technologies Holdings, Inc. reported that it acquired 100% of JandB Holdings, LLC through a share exchange completed on August 18, 2025. The consideration is 120,000 shares of NeOnc common stock with an attributed value of $25 per share, reduced by a number of shares equal to transaction fees divided by $25. JandB is now a wholly owned subsidiary. The company also announced that director Dr. Ming-Fu Chiang resigned from the board, with no disagreement cited, and will continue on the science advisory board. On the same day, the board elected Ishwar Puri, a senior vice president for research and innovation at the University of Southern California and former engineering dean at McMaster University, as a director, in connection with the JandB transaction. NeOnc also issued a press release with second-quarter financial results, which is furnished as an exhibit.
NeOnc Technologies Holdings, Inc. filed an 8-K dated August 18, 2025 reporting a material event: a declaration of non-reliance on previously issued financial statements or a related audit report or completed interim review. The filing is signed by Amir Heshmatpour. The notice is brief and does not include financial tables, earnings data, or details explaining the reasons for the non-reliance statement. The disclosure indicates the company has identified an issue significant enough to withdraw confidence in earlier financial reporting, but the document provides no additional context, corrective actions, timelines, or quantified impacts.
NeOnc Technologies Holdings, Inc. disclosed two material corporate developments. On August 7, 2025 the company announced it was awarded $2.5 million in NIH STTR grants to advance its drug candidate NEO212 for gliomas and leukemia; the announcement is furnished as Exhibit 99.1. On August 11, 2025 NeOnc announced the official incorporation of NuroMENA Holdings Ltd. by the Abu Dhabi Global Market; that announcement is furnished as Exhibit 99.2.
The filing notes these press releases are furnished (not deemed "filed") for purposes of Section 18 of the Exchange Act and are not incorporated by reference into other filings except as expressly stated. The company’s common stock trades as NTHI on Nasdaq and it is identified as an emerging growth company in the filing.